Printer Friendly

Takeda submits marketing authorisation application for gut-selective humanised monoclonal antibody.

M2 EQUITYBITES-March 8, 2013-Takeda submits marketing authorisation application for gut-selective humanised monoclonal antibody(C)2013 M2 COMMUNICATIONS http://www.m2.com

Takeda Pharmaceutical Company, a research-based global pharmaceutical company, has submitted a marketing authorisation application requiring approval from the European Medicines Agency for its investigational, gut-selective humanised monoclonal antibody.

It is reported today that the antibody is to be used for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

Vedolizuma, a monoclonal antibody, provokes alpha4beta7 integrin expressed on a subset of circulating white blood cells, and treats most common types of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 8, 2013
Words:117
Previous Article:Cerberus looks to up Seibu interest to 33.4% - report.
Next Article:RetroSense receives notice of allowance for patent application No. 12/299,574.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters